Available On-Demand
Join our panel of multidisciplinary experts as they consider the longevity and compliance of cell and gene therapies.
As part of a brand new Accelerating Science Feature, SelectScience® will bring together experts and industry leaders in cell and gene therapy research, manufacturing, and compliance to discuss the first-ever approval of a gene-editing-based therapy Casgevy.
Exploring the potential of other innovative cell and gene therapy types alongside this critical approval, key topics such as monitoring long-term efficacy, identifying potential risks, improving manufacturing processes, optimizing dosing regimens, and developing robust monitoring systems, will also be discussed.
Whether you are a researcher, healthcare professional, industry representative, or simply interested in the future of medicine, this event will equip you with valuable knowledge and understanding of the challenges and potential solutions related to the longevity and compliance of cell and gene therapies.
Key learning objectives
- Discuss the first-ever approval of gene-editing-based therapy Casgevy for sickle cell disease.
- Explore the challenges and advancements in ensuring the safety and long-term therapeutic effects of cell and gene therapies.
- Examine the complexities involved in researching, developing and producing these treatments, and the types of solutions available.
- Discuss the hurdles faced in achieving regulatory compliance for cell and gene therapies.
Who should attend
- Cell and gene therapy researchers, healthcare professionals, industry representatives, or those simply interested in the future of this field of medicine.
Thank you to our sponsors:
Presenters
Cameron Smith-Craig
Editorial Team
Selectscience
Dr. Priya Chockalingam
Vice President, Head of Clinical BioAnalytics & Translational Sciences
Beam Therapeutics
Dr. Priya Chockalingam holds a Ph.D. in biochemistry and, with over 20 years of experience in translational medicine, bioanalytics, biomarkers, and diagnostics, she currently serves as the VP and Head of Clinical Bioanalytics & Translational Sciences at Beam Therapeutics. In this role, she oversees a team that collaborates across research and development, focusing on bioanalytical, biomarker, and translational strategies, with a strong emphasis on implementing these approaches for a diverse range of clinical programs. These programs encompass areas such as hematology, immunology, oncology, and rare genetic diseases, and involve cutting-edge technologies like base editing, auto/allo cell therapies, and innovative delivery methods like lipid nanoparticles (LNP).
Dr. Torsten Wuestefeld
Associate Professor of Molecular Metabolism at the Lee Kong Chian School of Medicine, Nanyang Technological University / Group Leader of the Laboratory of In Vivo Genetics and Gene Therapy
Genome Institute of Singapore, A*STAR
r. Torsten Wuestefeld is currently associate professor of molecular metabolism at the Lee Jong Chan School of Medicine, Nanyang Technological University with a joint appointment as group leader of the Laboratory of In Vivo Genetics and Gene Therapy at the Genome Institute of Singapore, A*STAR. He is also the scientific co-founder of LERNA Biopharma formerly known as Cargene Therapeutics, a Singaporean biotech company developing siRNA therapies for liver disease. Dr. Torsten Wuestefeld graduated with a Diploma (Master of Science) from the Department of Biology at the Leibniz University Hannover, Germany and obtained his Doktor rerum naturalium (PhD) from the Department of Chemistry, Leibniz University Hannover, Germany. While pursuing his doctoral studies, he conducted research on signal transduction pathways during liver regeneration at the Medical School Hannover, Germany. He has more than 20 years of experience dissecting liver biology. Through in vivo functional genetics he identified important regulators of liver regeneration & disease. He was the first to describe MKK4 as a master regulator of liver regeneration. Based on his research a MKK4 specific kinase inhibitor was developed and passed phase 1 clinical trial last year. Currently he is developing among other things nucleic acid therapeutics for liver disease.
Jay Tanna, MS, RAC
Quality Assurance Manager, Cellular Therapy Laboratory
Children’s National Hospital